Clinical Trial Detail

NCT ID NCT02658981
Title Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

gliosarcoma

glioblastoma multiforme

Therapies

Relatlimab

Urelumab

Nivolumab + Urelumab

Nivolumab + Relatlimab

Age Groups: senior adult

No variant requirements are available.